Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
Date:1/22/2013

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly soluble drugs, unstable compounds, and sophisticated controlled release patterns. He has extensive experience in developing parenteral products; oral tablets, capsules, and liquids; nebulizer products; dry powder inhalers; and topicals. His experience covers product processing from bench top to commercial manufacturing where he has developed processes for emulsification, powder milling, steam sterilization; aseptic manufacture; lyophilization; and separation of proteins.

Dr. Rehlaender's analytical expertise is primarily in solids characterization, including differential scanning calorimetry, thermogravimetric analysis, dynamic vapor sorption, powder flow measurement, and particle sizing using laser diffraction, photon correlation spectroscopy; electrozone sensing, and light obscuration.

About PharmaDirections

PharmaDirections is a consulting and project management company with a unique approach to managing preclinical, CMC and regulatory affairs programs. We provide strategic planning then oversee and direct pharmaceutical contract research using our own scientific experts and project managers. We are a comprehensive resource for virtual pharmaceutical and biotech companies who need to stay lean by outsourcing their R&D activities.

http://www.PharmaDirections.com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341546.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... R&D program for the development of future natural products for ... research and development center in Israel ... Stockton has a variety of products adapted ... active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to control ...
(Date:2/5/2016)... Feb. 5, 2016 ATCC, the premier global ... assist the medical and life science researchers that are ... infection.   CDC website . ... Zika virus is a single-stranded RNA virus of the ... Nile, Dengue and Chikungunya Viruses. Zika virus is transmitted ...
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:1/11/2016)... Calif. , Jan. 11, 2016 Synaptics ... human interface solutions, today announced that its ClearPad ® ... integration (TDDI) products won two separate categories in the ... Mobile Innovator and Best Technology Breakthrough. The Synaptics ® ... cost, a simplified supply chain, thinner devices, brighter displays ...
(Date:1/8/2016)... January 8, 2016 NXTD ), ... WorldVentures ® , a privately held leading direct seller ... Inc. 5000 fastest-growing company announced that on December ... $2 million in Nxt-ID to develop a proprietary new ... Wocket ® , a unique smart wallet that serves ...
(Date:1/7/2016)... Jan. 7, 2016  A United States District Court ... court in the country to interpret a biometric privacy ... go forward against the photo website Shutterfly brought by ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and THISLIFE, INC ... that Shutterfly violates the Illinois Biometric Privacy Act by ...
Breaking Biology News(10 mins):